Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), GE Aerospace ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk ...

Eli Lilly (NYSE:LLY) has received regulatory approval to market its Alzheimer’s therapy Kisunla (donanemab) in Australia, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

makes inroads into its market share and as its pipeline of new drugs has failed to impress investors. Eli Lilly has seen US prescriptions for its Zepbound obesity shot surpass Wegovy since mid ...

Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are ...

Lars Rebien Sorensen becomes CEO after serving as the head of Novo's healthcare business. The company's enzymes business was ...